cycloheximide has been researched along with aclarubicin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mochizuki, T; Okazaki, T; Sawada, H; Tashima, M; Uchino, H | 1 |
| Harada, M; Ikeda, K; Ishimaru, F; Kiguchi, T; Kiura, K; Miyazono, T; Nakata, Y; Niiya, K; Shibakura, M; Shinagawa, K | 1 |
2 other study(ies) available for cycloheximide and aclarubicin
| Article | Year |
|---|---|
Magnesium deprivation inhibits the expression of differentiation-related phenotypes in human promyelocytic leukemia HL-60 cells.
Topics: Aclarubicin; Amanitins; Bucladesine; Calcitriol; Cell Differentiation; Cell Division; Cell Line; Cycloheximide; Dimethyl Sulfoxide; Drug Interactions; Humans; Leucine; Leukemia, Myeloid, Acute; Magnesium Deficiency; Naphthacenes; Oncogenes; Peptide Chain Elongation, Translational; Phenotype; RNA, Messenger; Tetradecanoylphorbol Acetate; Tretinoin | 1987 |
Induction of urokinase-type plasminogen activator by the anthracycline antibiotic in human RC-K8 lymphoma and H69 lung-carcinoma cells.
Topics: Aclarubicin; Antibiotics, Antineoplastic; Antioxidants; Blotting, Northern; Cell Nucleus; Cycloheximide; Dactinomycin; Dose-Response Relationship, Drug; Doxorubicin; Humans; Lung Neoplasms; Lymphoma; Oligonucleotide Array Sequence Analysis; Protein Synthesis Inhibitors; RNA, Messenger; Time Factors; Tumor Cells, Cultured; Urokinase-Type Plasminogen Activator | 2001 |